SC 13G/A: Pyxis Oncology, Inc.

AI Summary

SC 13G/A filing by Pyxis Oncology, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie

Filing Documents

• tm2427363d3_sc13ga.htm (SC 13G/A) — 55KB
• 0001104659-24-114823.txt ( ) — 56KB

(a) Name of Issuer

Item 1(a) Name of Issuer Pyxis Oncology, Inc. (the “ Issuer ”)

(b) Address of Issuer’s Principal Executive Offices

Item 1(b) Address of Issuer’s Principal Executive Offices 321 Harrison Avenue, Boston, Massachusetts 02118

(a) Name of Person Filing

Item 2(a) Name of Person Filing This Schedule 13G/A is being jointly filed by Bayer World Investments B.V. (“ BWI ”) and Bayer Aktiengesellschaft (“ Bayer ”) (collectively, the “ Reporting Persons ”).

(b) Address of Principal Business Office, or if none, Residence

Item 2(b) Address of Principal Business Office, or if none, Residence The business address for BWI is Siriusdreef 36, 2132 WT Hoofddorp, The Netherlands. The business address for Bayer is Bayerwerk, Kaiser-Wilhelm-Allee 1, 51368 Leverkusen, Germany.

(c) Citizenship

Item 2(c) Citizenship The Reporting Persons are citizens of: BWI — The Netherlands Bayer — Germany

(d) Title of Class of Securities

Item 2(d) Title of Class of Securities Common Stock, par value $0.001 per share (“ Common Stock ”)

(e) CUSIP Number

Item 2(e) CUSIP Number 747324101

Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)

Item 3. Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c) Not Applicable Item 4. Ownership (a) BWI is the direct beneficial owner of an aggregate of 2,742,338 shares of Common Stock, which represents 4.7% of the Issuer’s outstanding Common Stock based upon 58,942,243 shares outstanding on August 13, 2024 as reported by the Issuer in its Form 10-Q as filed with the SEC on August 14, 2024. CUSIP No. 747324101 Page 5 of 7 Pages BWI is an indirect, wholly owned subsidiary of Bayer. Accordingly, Bayer may be deemed to be an indirect beneficial owner of the shares of Common Stock beneficially owned directly by BWI. (b) Percent of class: BWI — 4.7% Bayer — 4.7% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: BWI — 2,742,338 Bayer — 2,742,338 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: BWI — 2,742,338 Bayer — 2,742,338 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the Reporting Person have ceased to be the beneficial owners of more than five percent of the class of securities, check the following:

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not Applicable

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not Applicable

Notice

Item 9. Notice of Dissolution of Group Not Applicable

Certification

Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. CUSIP No. 747324101 Page 6 of 7 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: November 6, 2024 BAYER WORLD INVESTMENTS B.V. By: /s/ Kati Schnuerer Kati Schnuerer, Managing Director BAYER AKTIENGESELLSCHAFT By: /s/ Thomas Hoffmann Thomas Hoffmann, Head of Treasury CUSIP No. 747324101 Page 7 of 7 Pages EXHIBIT INDEX A. Joint Filing Agreement, dated February 11, 2022, by and between all the Reporting Persons (incorporated by reference to Exhibit A of the Schedule 13G filed with the SEC on February 11, 2022).